These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 17557984

  • 1. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 2. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 4. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 5. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 6. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [Abstract] [Full Text] [Related]

  • 7. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 8. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 9. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE, Ruiz AM, Monsalve MC, Berber A.
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [Abstract] [Full Text] [Related]

  • 10. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 11. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP, SCOUT Investigators.
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [Abstract] [Full Text] [Related]

  • 12. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [Abstract] [Full Text] [Related]

  • 13. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S, Hansen DL, Hilsted JC, Porsborg PA, Astrup AV, STORM Study Group.
    Ugeskr Laeger; 2001 May 21; 163(21):2935-40. PubMed ID: 11402974
    [Abstract] [Full Text] [Related]

  • 14. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep 21; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 15. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul 21; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 16. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Jul 21; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 17. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA, SAT Study.
    Exp Clin Endocrinol Diabetes; 2004 Apr 21; 112(4):201-7. PubMed ID: 15127325
    [Abstract] [Full Text] [Related]

  • 18. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar 21; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan 21; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 20. Effect of meal replacement on metabolic risk factors in overweight and obese subjects.
    König D, Deibert P, Frey I, Landmann U, Berg A.
    Ann Nutr Metab; 2008 Jan 21; 52(1):74-8. PubMed ID: 18319587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.